About – Sara Ekberg

Sara Ekberg, PhD

Principal Biostatistician

Sara is a biostatistician with over 10 years of experience working with register-based epidemiological research. She joined Red Door Analytics part-time (0.2FTE) in June 2022. She also works at the Department of Medicine, Karolinska Institutet, and in addition is affiliated with both Uppsala University and Lund University. Her research interests include cancer survival and survivorship issues. Sara is also an engaged lecturer with a passion for teaching statistics to non-statisticians.

Education

Selected publications

Ekberg S, Crowther MJ, Harrysson S, Jerkeman M, Smedby KE, Eloranta S. Patient trajectories after diagnosis of diffuse large B-cell lymphoma-a multistate modelling approach to estimate the chance of lasting remission. British Journal of Cancer, 2022

Ekberg S, Smedby KE, Albertsson-Lindblad A, Jerkeman M, Weibull CE, Glimelius I. Late effects in mantle cell lymphoma patients treated with or without autologous stem cell transplantation. Blood Advances, 2022

Fjordén K, Ekberg S, Kuric N, Smedby KE, Lagerlöf I, Larsen TS,  Jørgensen JM, de Nully Brown P, Jerkeman M. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. British Journal of Haematology 2022;196(2):437-440

Harrysson S, Eloranta S, Ekberg S, Enblad G, El-Galaly TC, Sander B, Sonnevi K, Andersson P-O, Jerkeman M, Smedby KE. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients. British Journal of Haematology 2022;198(2):267-277

Harrysson S, Eloranta S, Ekberg S, Enblad G, Jenkeman M, Wahlin BE, Andersson P-O, Smedby KE. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer Journal 2021;11(1):9

Ekberg S, Harrysson S, Jernberg T, Szummer K, Andersson P-O, Jerkeman M, Smedby KE, Eloranta S. Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study. Journal of Internal Medicine 2021;290(5):1048-1060

Ekberg S, Smedby KE, Glimelius I, Nilsson-Ehle H, Goldkuhl C, Lewerin C, Jerkeman M, Eloranta S. Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study. British Journal of Haematology 2020;189(6):1083-1092

Almqvist C, Ekberg S, Rhedin S, Fang F, Fall T, Lundholm C. Season of birth, childhood asthma and allergy in a nationwide cohort-Mediation through lower respiratory infections. Clinical & Experimental Allergy 2020;50(2):222-230

Ekberg S, Jerkeman M, Andersson P-O, Enblad G, Wahlin BE, Hasselblom S, Andersson TM-L, Eloranta S, Smedby KE. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. American Journal of Hematology 2018;93:1020-1028

Ekberg S, Ploner A, de Faire U, Pedersen NL, Bennet AM. Familial effects on survival after myocardial infarction: a registry-based sib-pair study. European Journal of Epidemiology 2012;27(12):911-4

Red Door Analytics AB is a registered company in Sweden

CEO: Michael Crowther
Org. number: 559351-8359